Ocuphire Pharma Investor Presentation Deck
Product Profile: Nyxol® + Low-Dose Pilocarpine (LDP) Combo
Moderate Action on Iris Dilator and Iris Sphincter Muscles for Near Vision Improvement
0.75% Nyxol
5
+
0.4%
HO
0.4% LDP
Iris Dilator
Muscle
Inhibition
Iris Sphincter
Muscle
Activation
Source: 1) Nyxol® data from 8 completed trials; Pilocarpine Product label and Literature
Evening drop
Daytime drop
●
●
●
Phentolamine (alpha1/2 antagonist) approved non-
ocular injectable indications decade(s) ago 505(b)(2)
Novel MOA on iris dilator with 24+ hour durability
Moderate 1+mm pupil reduction
No daytime redness w/ chronic evening dosing Nyxol
Well-tolerated with no systemic effects
Stable, preservative-free, single use vial
1.5 to 2.5 mm PD reduction moves toward
the pin-hole (2 to 2.5 mm, up to 3 mm)
Pilocarpine (cholinergic agonist) approved decades ago
Known MOA on sphincter muscle with potent miotic
effects at approved doses (1%, 2%, 4%)
Chronic daytime dosing of LDP
Low concentration avoids known tolerability issues:
➤ headache and browache
redness
accommodative spasm causing loss of distance
vision especially at night
Ocuphire
PHARMAView entire presentation